TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates17-03-2023
17-03-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - USFDA Pre-Approval Inspection Of Oral Oncology Manufacturing Facility, Gujarat
The USFDA conducted Pre-Approval Inspection [PAI] of our Oral-Oncology manufacturing facility at Bileshwarpura, Gujarat from 13-Mar-23 to 17-Mar-23. At the end of the inspection, we have been issued a 'Form 483' with 1 observation, which is procedural in nature. We will respond to the USFDA within stipulated timeline and work closely with USFDA to address the observation at the earliest.17-03-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement in respect of Notice of Hearing of Petition Ref : Scheme of Arrangement in the nature of Amalgamation of Curatio Health Care (I) Private Limited with Torrent Pharmaceuticals Limited16-03-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201518-02-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201515-02-2023
Torrent Pharmaceuticals forays into OTC segment with calcium supplement
Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.14-02-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates03-02-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Conference call with Analysts / Investors on Financial Results for the quarter and nine months ended 31st December, 202201-02-2023
Buy Torrent Pharmaceuticals; target of Rs 1915: Anand Rathi
Anand Rathi is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1915 in its research report dated January 27, 2023.31-01-2023
Buy Torrent Pharmaceuticals, target of Rs 1788: Sharekhan
Sharekhan is bullish on Torrent Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1788 in its research report dated January 27, 2023.30-01-2023